lirafugratinib

Lirafugratinib is a highly selective FGFR2 inhibitor (formerly RLY-4008) that Relay Therapeutics designed and out-licensed to Elevar Therapeutics in December 2024 for up to $500M in milestones plus double-digit royalties [6]. The deal hit at a moment when Relay was redirecting capital toward its PI3Kα program (zovegalisib, RLY-2608) and chose milestone-and-royalty optionality over building its own commercial oncology footprint [6]. Elevar subsequently filed an NDA for FGFR2-altered cholangiocarcinoma based on ReFocus data and received FDA Priority Review with a PDUFA target action date of September 27, 2026 [9]. The Phase 2 trial discussed here (NCT07359820) is a separate basket study testing lirafugratinib in non-cholangiocarcinoma solid tumors carrying FGFR2 fusions or rearrangements [3]. The bet: a clean FGFR2-only inhibitor avoids the hyperphosphatemia and diarrhea that limit pan-FGFR drugs already on market for cholangiocarcinoma.

Novel selectivity profile within a validated target class, currently in Phase 2 expansion. Relay built lirafugratinib using motion-guided drug design, computationally sampling the conformational ensemble of the FGFR2 kinase across its dynamic states rather than designing against a single static crystal structure [10]. The ReFocus Phase 1/2 trial in FGFR2-fusion cholangiocarcinoma reported an objective response rate of 88.2% in FGFR-inhibitor-naive patients at the 70 mg recommended Phase 2 dose, with roughly 45% response in pre-treated patients - exceptional efficacy that drove the December 2024 out-licensing deal [7]. Elevar took global development and commercialization rights and has since filed an NDA in second-line FGFR2-altered cholangiocarcinoma; FDA granted Priority Review with a PDUFA target action date of September 27, 2026 [9]. The basket trial covered here (NCT07359820) opened in 2025 under Elevar sponsorship and is actively recruiting roughly 30 patients with non-CCA solid tumors carrying FGFR2 fusions or rearrangements [3]. No FDA designations have been publicly reported on this specific basket protocol, though the CCA program received fast-track and breakthrough designations under Relay sponsorship. Expected basket readout sits in 2027 territory at current pace; the CCA decision in September 2026 is the near-term value driver.

FGFR2 sits on cell surfaces like an antenna. When a growth factor binds, the receptor tells the cell to divide [8]. In certain cancers, especially intrahepatic cholangiocarcinoma (a rare bile-duct cancer), chromosomal rearrangements fuse FGFR2 to partner genes and jam the receptor into the always-on position. About 10-15% of intrahepatic CCA patients carry these fusions; rates run 1-3% in breast, gastric, lung, and other tumors. The mechanism is well validated. Pemigatinib (Incyte's Pemazyre) and futibatinib (Taiho's Lytgobi) are FDA-approved for FGFR2-fusion CCA with response rates in the 35-40% range [4][5]. The problem with those drugs: they are pan-FGFR inhibitors hitting FGFR1, 3, and 4 alongside the target. Blocking FGFR1 causes hyperphosphatemia, where phosphate accumulates in blood and sometimes calcifies soft tissue. Blocking FGFR4 causes diarrhea. Both effects drive dose reductions and treatment interruptions that erode efficacy at the patient level. Lirafugratinib binds the FGFR2 kinase pocket with reported greater than 200-fold selectivity over FGFR1, designed against the protein's dynamic conformations rather than its static structure [10]. In ReFocus the rate of grade 3 hyperphosphatemia was substantially lower than with pan-FGFR drugs [7]. The thesis is straightforward: keep the FGFR2 efficacy, lose the FGFR1 and FGFR4 toxicity, treat at full dose for longer.

NCT07359820 is open-label, single-arm, Phase 2, enrolling roughly 30 patients with non-CCA solid tumors harboring FGFR2 fusions or rearrangements identified by next-generation sequencing [3]. Primary endpoint is objective response rate per RECIST v1.1, assessed by an Independent Review Committee. Secondary endpoints include duration of response, progression-free survival, and safety. No comparator arm, which is standard for biomarker-defined rare-alteration basket studies. Sponsor is Elevar Therapeutics; status on ClinicalTrials.gov is recruiting, with site activation concentrated in the US and Asia. Design concerns are real. Thirty patients spread across a basket of tumor types (likely breast, gastric, non-small cell lung, pancreatic, and others) means single-digit patient counts per histology. That produces noisy efficacy estimates inside each indication and makes it hard to identify which tumor types respond best. The trial functions as a hypothesis-generator for tumor-specific expansion cohorts rather than a registrational study. ORR is the right endpoint here; PFS or OS in a 30-patient open-label basket would be uninterpretable without a control. The historical comparator most often cited is pemigatinib's FIGHT-207, which reported roughly 25% pooled ORR across non-CCA FGFR-altered tumors - but that figure mixed FGFR1, 2, and 3 alterations and included amplifications and mutations that respond worse than fusions, so it understates the relevant bar. Pemigatinib's FGFR2-fusion subgroup ORR is the apples-to-apples reference; lirafugratinib will need to clear that to make the tumor-agnostic case.

Our model puts this drug's chance of eventual approval at 8%. It starts from the historical approval rate for Phase 2 drugs in this area - about 13% - then adjusts based on ten facts about the trial and its sponsor. The estimate goes up because the trial has more secondary endpoints than usual and uses a non-randomized design; it goes down because the sponsor has a thin approval record and earlier-phase results were weak. The remaining factors are close to average for this stage, so they leave the final number near the base rate.

Resistance is the published risk. Facchinetti et al. (Clin Cancer Res 2026) and Ellis et al. (Ann Oncol 2026) both cataloged recurring FGFR2 kinase domain mutations, including V565 gatekeeper substitutions and molecular-brake mutations, emerging in patients progressing on lirafugratinib [1][2]. Gatekeeper mutations change a single amino acid in the drug-binding pocket, physically blocking the inhibitor from fitting; molecular-brake mutations lock the kinase in an active state that the drug was not designed to bind. Together they let the cancer keep growing despite the drug, and lirafugratinib's tight selectivity profile means the mutations that defeat it are largely the same ones that defeat older FGFR drugs - leaving no clear second-line option today. KIN-3248 (Kinnate) is in Phase 1 development specifically to cover FGFR2 gatekeeper and molecular-brake mutations [11], so the second-line slot is contested but not solved. Efficacy risk in this specific Phase 2: non-CCA FGFR2 fusion tumors are biologically heterogeneous. Lung adenocarcinoma fusions, for instance, often involve different partner genes than CCA fusions, and response patterns track the partner. A 30-patient basket will not resolve which tumors respond and which do not [3]. Safety risk: even with FGFR1 selectivity, some hyperphosphatemia and ocular adverse events appeared in ReFocus. Not deal-breakers but worth tracking. Commercial risk is the larger issue. Pemigatinib's annual revenue tops out near $80-100M despite a strong response rate in CCA; the market is small and competitive. Non-CCA FGFR2-fusion patients are even rarer. Elevar Therapeutics is a specialty oncology player better known for HCC work, not a global oncology powerhouse [6]. Whether they can run trials at the cadence Relay set is an open question. For Relay shareholders the asset is a royalty stream that depends on Elevar's execution; for Elevar, differentiation against entrenched pan-FGFR competitors at the prescriber level is the variable that matters.

Two distinct catalysts, only one of which is this trial. The near-term value driver is the NDA decision for FGFR2-altered cholangiocarcinoma at the September 27, 2026 PDUFA date [9] - that approval (and the subsequent commercial ramp under Elevar) determines whether the franchise economics work at all. The non-CCA basket discussed here (NCT07359820) is secondary signal, useful for label expansion arguments and tumor-agnostic pricing if data are strong, but not where the franchise gets made or broken [3]. The data point that would make the basket a real signal: ORR above 35% pooled, ideally with durable responses in at least two non-CCA tumor types, with breast and gastric the most likely winners based on prior pemigatinib data. Anything below 20% pooled ORR suggests FGFR2 fusion biology is more CCA-specific than the basket thesis allows. Check back at the next ASCO or ESMO cycle, most likely 2027, for either interim basket data or the first full Elevar-sponsored CCA commercial readout. Competitive position: KIN-3248 is the closest follow-on (FGFR2/3 selective, Phase 1) and is positioned for the resistance setting rather than head-to-head with lirafugratinib in front-line FGFR2-fusion CCA [11]; the selectivity moat is durable for now. For investors tracking Relay Therapeutics, this is a milestone-and-royalty optionality bet - the December 2024 out-license freed Relay to concentrate capital on its PI3Kα and Vps34 programs, and lirafugratinib is essentially monetized for them [6]. The combination of validated mechanism plus modest commercial ceiling plus documented on-target resistance puts the asset firmly in the meaningful-niche category, not category-defining.